Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $FCSC Due to Rising Prevalence of Cancer in U.S., Cancer Therapy Market Showing Rapid Growth
September 16, 2019 Palm Beach, FL –September 16, 2019 – The global cancer therapy market looks like it will continue trend to continue its growth… worldwide. Cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with spec...
In case you are interested FCSC - Due to Rising Prevalence of Cancer in U.S., Cancer Therapy Market Showing Rapid Growth
News: $FCSC Fibrocell to Present at BIO International Convention 2019
EXTON, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will p...
Find out more https://marketwirenews.com/news-releases/fibrocell-to-present-at-bio-international-convention-2019-8269090.html
News: $FCSC Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
EXTON, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the R...
Got this from https://marketwirenews.com/news-releases/fibrocell-receives-fda-regenerative-medicine-advanced-therapy-designation-for-fcx-007-gene-therapy-for-the-treatment-of-rdeb-8261984.html
I agree with that
Added this to my list yesterday. Can't play all of 'em but this one is shaping up nicely.
Parabolic move is coming here, question is just when.
Everything is out now. Even Form 4's.
8k and Form 4's out.
I wonder who is manipulating this?
ClayTraders said no
We will be lucky to back at 2.54 .. such a great PR and either the company dumped on it. Or got shorted down
I know..just have to stay strong against the blatant manipulation. This moves fast. We seen that.
Wow. We went from testing $3 to trying not to test $2
Highly doubt it.. might close under 2 bucks
It's very possible
how should it have been otherwise
I think - that we will close green
So you think the 30 plus million was all manipulation?
it will not be boring
I agree. It's quiet around here now.
Let's see what happens next few days
Right!!! It is stupid. They should just let it go already. At least over $3
Way less volume too
Someone is trying to keep it in this area. Manipulation at it's finest.
Let's see what happens today
Right. I still think it's manipulation to load cheap. Before I does and control the float. Or either some shorting too.
Either way we should have been over $5 minimum
O..ok gotcha. It's probably coming.
News yesterday... previous pr they released an 8k right after
They have yet to drop an 8k aswell
If the company is diluting it's a damn shame cuz this should be well over 10 bucks
Me too. It's crazy.
Prob gonna ride out today and if still being diluted or manipulated gonna cut it
reading a News is not enough-you have to understand them too
Perfect bullshit-you've not understood the NEWS
Got me some $2.50's on the dip today. Not too sure about this one. Good news, but company certainly diluted today.
this will have Consequences
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7054
|
Created
|
01/09/08
|
Type
|
Free
|
Moderators |
Fibrocell Science, Inc. is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications.
Welcome to the new Fibrocell Science, Inc. and our new web site. I am pleased to have this opportunity to share my enthusiasm with you as Fibrocell’s Chairman of the Board of Directors.
We have been extremely busy charting the course for Fibrocell as a biotechnology company focused on the power of regenerative fibroblast cells for aesthetic, medical and scientific applications.
We have a challenging and exciting path before us as we continue to prepare for the U.S. Food & Drug Administration response to the biologics license application (BLA) we submitted in March 2009 for the use of Laviv™ (azficel-T)*, Fibrocell Science’s lead therapy, for the treatment of moderate to severe nasolabial fold wrinkles. The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, which reviewed our therapy on October 9, 2009, voted 11 yes to 3 no that the data presented demonstrated efficacy, and 6 yes to 8 no that the data demonstrated safety, both for the proposed indication.
We are pleased to begin operations under Fibrocell Science, Inc., having reorganized the former Isolagen, Inc. and significantly reduced the company’s debt from US $81M to US $6M. We now look forward to an ambitious evaluation of our clinical priorities to maximize the potential use of our therapy in additional indications such as full-face rejuvenation, acne scars, burn scars and dental applications.
We have considerable work before us at Fibrocell Science, and we welcome the challenge. I join Fibrocell with extensive commercial experience from GlaxoSmithKline, where I most recently served as senior vice president, Pharmaceuticals and Vaccines. I am proud to have a strong management team helping guide this new company, including Declan Daly, former Isolagen chief executive officer, who was instrumental in our reorganization and remains committed to the company’s success.
Thank you for your interest in the new Fibrocell Science, Inc.
Sincerely,
David Pernock
Chairman
Fibrocell Science, Inc.
Fibrocell Therapy is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient’s own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy. Fibroblasts are cells that contribute to the formation of connective tissue fibers. These matrix fibers are critical to the strength and elasticity of the skin.
Broadly, the regenerative effects of fibroblasts include:
- The ability to synthesize the extracellular matrix components and, thus, to improve skin texture,
- The secretion of matrix fibers, including collagen, and
- Playing a critical role in wound healing and tissue repair.
The Company prepares the Fibrocell Therapy through a streamlined process that begins with removing a small sample of cells from behind a patient’s ear and sending that sample to the Fibrocell cGMP facility. The process expands fibroblasts into tens of millions of new cells, which are then formulated into an autologous cellular therapy. Cells are frozen and used for multiple treatment sessions. The therapy is reintroduced into the patient’s skin by injection, which we believe results in an increase in the local fibroblast population, collagen formation and assists the body’s own regenerative healing process. In controlled clinical studies, a significant improvement in the appearance of nasolabial fold wrinkles was observed after injecting Fibrocell Therapy.
Regenerative fibroblast cells may have potential in use for broad aesthetic, medical and scientific applications. The Fibrocell Therapy for aesthetics, azficel-T, proposed brand name Laviv™, is currently under review by the FDA for the treatment of moderate to severe nasolabial fold wrinkles. Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for azficel-T.
The company manufactures its cell therapy at a cGMP manufacturing facility in Pennsylvania.
Fibroblasts are cells that contribute to the formation of connective tissue fibers. Fibrocell's future scientific focus will be on regenerative medicine that leverages the direct and indirect therapeutic benefit of fibroblasts.
Fibrocell has submitted a biologics license application to the U.S. Food & Drug Administration (FDA) based on its Phase III clinical trials evaluating the efficacy and safety of its azficel-T in treating moderate to severe nasolabial fold wrinkles in patients older than 18 year of age.
In addition to wrinkle correction, Fibrocell has obtained statistically significant results in a Phase II/III acne scar clinical trial and a Phase II open label full face rejuvenation study. Fibrocell also has results in early burn scars and periodontal disease studies.
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.
Fibrocell Therapy is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient's own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy to regenerate skin. Fibroblasts are cells that contribute to the formation of connective tissue fibers. The Fibrocell Therapy for aesthetics, azficel-T, proposed brand name Laviv™ is currently under review by the FDA for the treatment of moderate to severe nasolabial fold wrinkles.
Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for its Fibrocell Therapy, which is manufactured at a cGMP cell therapy manufacturing facility at its headquarters in Pennsylvania.
OCTOBER 09, 2009
Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
OCTOBER 06, 2009
Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |